ROCURONIUM BROMIDE INJECTION SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Купи го сега

Активна съставка:

ROCURONIUM BROMIDE

Предлага се от:

JUNO PHARMACEUTICALS CORP.

АТС код:

M03AC09

INN (Международно Name):

ROCURONIUM BROMIDE

дозиране:

10MG

Лекарствена форма:

SOLUTION

Композиция:

ROCURONIUM BROMIDE 10MG

Начин на приложение:

INTRAVENOUS

Броя в опаковка:

15G/50G

Вид предписание :

Prescription

Терапевтична област:

NEUROMUSCULAR BLOCKING AGENTS

Каталог на резюме:

Active ingredient group (AIG) number: 0126317001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2020-05-05

Данни за продукта

                                _PRODUCT MONOGRAPH: Rocuronium Bromide Injection _
Page 1 of 33
PRODUCT MONOGRAPH
Pr
ROCURONIUM BROMIDE INJECTION
10 mg / mL, Solution for Injection, 5 mL vial
Sterile and Preservative Free
Non-depolarizing Skeletal Neuromuscular Blocking Agent
Juno Pharmaceuticals Corp.
402-2233 Argentia Road
Mississauga, Ontario
L5N 2X7
Date of Revision:
May 5, 2020
Submission Control No.: 238579
_PRODUCT MONOGRAPH: Rocuronium Bromide Injection _
Page 2 of 33
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
11
DOSAGE AND ADMINISTRATION
.............................................................................
12
OVERDOSAGE
................................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 17
STORAGE AND STABILITY
.........................................................................................
24
SPECIAL HANDLING INSTRUCTIONS
......................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 25
PART II: SCIENTIFIC INFORMATION
..............................................................................
26
PHARMACEUTICAL INFORMATION
.........................
                                
                                Прочетете целия документ
                                
                            

Документи на други езици

Данни за продукта Данни за продукта френски 05-05-2020

Сигнали за търсене, свързани с този продукт

Преглед на историята на документите